Sat, Mar 02, 2024
"Aurobindo Pharma Limited is pleased to announce that it has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Fingolimod Capsules, 0.5 mg, which is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Gilenya Capsules, 0.5 mg of Novartis Pharmaceuticals Corporation. The product will be launched in March 2024," said Aurobindo Pharma in a statement on Friday.
More >
Thu, May 25, 2023
Aurobindo Pharma Q4 result preview: Revenue may see a growth of 9 per cent to Rs 6,316 crore against Rs 5,809 crore logged in the year-ago period.
Fri, Feb 10, 2023
Pharma giant Aurobindo Pharma has announced an interim dividend of 300 per cent along with the December quarter results. The share of US business in the total business of the company has reached about 46.8%. Know the big things of Aurobindo Pharma's concall from Nupur.
Wed, Aug 24, 2016
The shares of Aurobindo Pharma were trading over 6% on the BSE on Wednesday a day after the company reported a 23.81% growth in its consolidated net profit at Rs 584.96 crore for the quarter-ended June 30, 2016.
By accepting cookies, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.
